Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TIZANIDINE HYDROCHLORIDE CRS (100 MG)

TIZANIDINE HYDROCHLORIDE CRS (100 MG)

64461-82-1

DISCOVER
LISINOPRIL FOR PEAK IDENTIFICATION CRS (15 MG)

LISINOPRIL FOR PEAK IDENTIFICATION CRS (15 MG)

83915-83-7

DISCOVER
ZANAMIVIR FOR ASSAY CRS (50 MG)

ZANAMIVIR FOR ASSAY CRS (50 MG)

139110-80-8

DISCOVER
ZANAMIVIR IMPURITY F CRS (10 MG)

ZANAMIVIR IMPURITY F CRS (10 MG)

03/02/4023

DISCOVER
EPLERENONE CRS (110 MG)

EPLERENONE CRS (110 MG)

107724-20-9

DISCOVER
EPLERENONE FOR SYSTEM SUITABILITY CRS (10 MG)

EPLERENONE FOR SYSTEM SUITABILITY CRS (10 MG)

107724-20-9

DISCOVER
EPLERENONE FOR PEAK IDENTIFICATION CRS (10 MG)

EPLERENONE FOR PEAK IDENTIFICATION CRS (10 MG)

107724-20-9

DISCOVER
DEMECLOCYCLINE FOR SYSTEM SUITABILITY CRS (10 MG)

DEMECLOCYCLINE FOR SYSTEM SUITABILITY CRS (10 MG)

64-73-3

DISCOVER
ZANAMIVIR FOR SYSTEM SUITABILITY CRS (10 MG)

ZANAMIVIR FOR SYSTEM SUITABILITY CRS (10 MG)

NA

DISCOVER
LISINOPRIL FOR SYSTEM SUITABILITY A CRS (15 MG)

LISINOPRIL FOR SYSTEM SUITABILITY A CRS (15 MG)

83915-83-7

DISCOVER
FLUOCINOLONE ACETONIDE FOR SYSTEM SUITABILITY CRS (15 MG)

FLUOCINOLONE ACETONIDE FOR SYSTEM SUITABILITY CRS (15 MG)

67-73-2

DISCOVER
FLUOCINOLONE ACETONIDE FOR PEAK IDENTIFICATION CRS (10 MG)

FLUOCINOLONE ACETONIDE FOR PEAK IDENTIFICATION CRS (10 MG)

NA

DISCOVER